Genfit: Milestone Achieved as a Compound Developed in Partnership Enters the Clinic
News May 06, 2010
Thanks to the joint efforts of the research teams of the two companies, a ‘first-in-class’ compound with an original mechanism of action for the treatment of cardiometabolic disorders is today entering clinical trials.
Jean-François Mouney, Chairman of GENFIT’s Management Board, declared: “We are very pleased to see a molecule originating from one of our research partnerships successfully achieve an important phase in its development. This provides strong recognition by the pharmaceutical industry of our scientific expertise and of the relevance of our research targets. This is the second program to enter clinical trials from this strategic collaboration initiated 8 years ago. This new achievement underlines the talent of our research teams, as well as those of our partner. We are confident that our innovative and collaborative approach will provide an efficient therapeutic strategy for cardiometabolic diseases and associated causes of mortality and morbidity.”
In addition to this initial milestone, GENFIT will potentially receive further clinical development-based milestone payments, as well as royalties on future sales.
New Studies Demonstrate Risk Reduction Potential of Heat-Not-Burn Tobacco Products and e-CigarettesNews
Data presented at the Society of Toxicology Annual Meeting (SOT) have demonstrated the potential of two different heat-not-burn tobacco products and e-cigarettes to reduce the risk of smoking-related diseases, in comparison to continued use of conventional cigarettes.READ MORE
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018